2019 set the tone for innovative therapies in the cell and gene therapy space along with huge interest from Big Biotech. With an expected double
“Cross border access”, “hub models”, “highly centralised access models” are only a few buzz words to refer to the pathway that enables European Union (EU)
By Ciaran Cassidy, Analyst Email: ccassidy@partners4access.com Colombia, like much of Latin America, is receiving attention from the pharmaceutical industry as an emerging market (1). Through
By Jack Rawson, Analyst Email: jrawson@partners4access.com At first glance Mexico presents a significant opportunity for drug manufacturers, with a large population of over 126 million,
2019 is expected to a strong year for the orphan drug industry with an expected 10% surge in sales growth. Contributing to this growth will
How drug repurposing could help drive orphan drug access if pharma can accept the risks By Nader Murad, Senior Analyst Email: nmurad@partners4access.com The US National
By Christina Poschen, Consultant Email: cposchen@partners4access.com Background Since 2004, the European Union’s centralised drug approval is in place, allowing manufacturers to submit just one application to
A US and EU perspective By Daniele Severi Bruni & Sophie Schmitz What’s the idea? Payer concerns over increasing cost of therapies and uncertainty of
Chimeric Antigen Receptor T-cell (CAR-T) therapies, which use a patient’s own immune cells to fight cancer, are one of the most exciting breakthroughs in cancer
